JP2023542539A5 - - Google Patents
Info
- Publication number
- JP2023542539A5 JP2023542539A5 JP2023518849A JP2023518849A JP2023542539A5 JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5 JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023518849 A JP2023518849 A JP 2023518849A JP 2023542539 A5 JP2023542539 A5 JP 2023542539A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- human
- mouse
- tumor
- human immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083016P | 2020-09-24 | 2020-09-24 | |
| US202063083003P | 2020-09-24 | 2020-09-24 | |
| US63/083,003 | 2020-09-24 | ||
| US63/083,016 | 2020-09-24 | ||
| PCT/US2021/051734 WO2022066894A1 (en) | 2020-09-24 | 2021-09-23 | Humanized mouse models for assessing immune cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542539A JP2023542539A (ja) | 2023-10-10 |
| JP2023542539A5 true JP2023542539A5 (https=) | 2024-07-30 |
Family
ID=80845843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518849A Pending JP2023542539A (ja) | 2020-09-24 | 2021-09-23 | 免疫細胞療法を評価するためのヒト化マウスモデル |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12196744B2 (https=) |
| EP (1) | EP4216971A4 (https=) |
| JP (1) | JP2023542539A (https=) |
| KR (1) | KR20230074758A (https=) |
| AU (1) | AU2021347320A1 (https=) |
| CA (1) | CA3196823A1 (https=) |
| IL (1) | IL301634A (https=) |
| WO (1) | WO2022066894A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2937797T3 (es) | 2017-04-17 | 2023-03-31 | Jackson Lab | Método de determinación de la toxicidad de un fármaco inmunomodulador para el uso en seres humanos |
| WO2024029561A1 (ja) * | 2022-08-02 | 2024-02-08 | 学校法人東海大学 | 担がん－免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法 |
| CN117686676B (zh) * | 2023-12-15 | 2025-05-30 | 扬州大学 | 一种基于多水平生物标志物响应法评价水中污染物转代生物效应的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| US7105158B1 (en) | 1992-11-16 | 2006-09-12 | The Corporation Of Mercer University | Methods of administering microencapsulated materials for immune modulated diseases |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US20060116321A1 (en) | 2004-07-01 | 2006-06-01 | Robbins Paul D | Immunosuppressive exosomes |
| JP2007244268A (ja) | 2006-03-15 | 2007-09-27 | Osaka Prefecture Univ | イヌの造血前駆細胞を認識するモノクローナル抗体の製造方法 |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| US20080299091A1 (en) | 2007-04-06 | 2008-12-04 | International Stem Cell Corporation | Patient-specific stem cell lines derived from human parthenogenetic blastocysts |
| US20110082091A1 (en) | 2009-09-28 | 2011-04-07 | Theramab Gmbh | Method for Preclinical Testing of Immunomodulatory Drugs |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| EP2558576B1 (en) | 2010-04-14 | 2016-10-19 | Envigo RMS, Inc. | Hairless nod scid mouse |
| EP2422618A1 (en) * | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| SG10202008003VA (en) | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| CN104160272A (zh) | 2011-12-06 | 2014-11-19 | 麻省理工学院 | 利用人源化的小鼠来确定毒性 |
| CN103304669A (zh) | 2012-03-12 | 2013-09-18 | 复旦大学 | 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途 |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| ES2664352T3 (es) | 2013-03-22 | 2018-04-19 | Imperial Innovations Ltd | Método in vitro para evaluar respuestas de tormenta de citoquinas |
| HK1255123A1 (zh) * | 2015-06-23 | 2019-08-02 | The Jackson Laboratory | 具有患者衍生异种移植物的非hla匹配的人源化nsg小鼠模型 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| HUE066460T2 (hu) * | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| CN110740641A (zh) | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| ES2937797T3 (es) | 2017-04-17 | 2023-03-31 | Jackson Lab | Método de determinación de la toxicidad de un fármaco inmunomodulador para el uso en seres humanos |
| RU2019140867A (ru) * | 2017-05-12 | 2021-06-15 | Зе Джексон Лаборатори | Nsg мыши, не имеющие mhc класса i и класса ii |
| US20190091310A1 (en) * | 2017-09-26 | 2019-03-28 | Stephen E. Wright | Nonreleased il-12 for therapy of cancer |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| US12496338B2 (en) * | 2017-10-23 | 2025-12-16 | City Of Hope | CAR for treatment of HIV infection |
| CN110055223A (zh) * | 2018-01-19 | 2019-07-26 | 北京百奥赛图基因生物技术有限公司 | 一种B2m基因改造的免疫缺陷动物的制备方法及其应用 |
| JP7411578B2 (ja) * | 2018-06-01 | 2024-01-11 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 癌を治療するための物質及び方法 |
| US20220389092A1 (en) * | 2019-04-05 | 2022-12-08 | The Regents Of The University Of California | Methods and compositions involving chimeric binding polypeptides |
-
2021
- 2021-09-23 KR KR1020237013626A patent/KR20230074758A/ko active Pending
- 2021-09-23 AU AU2021347320A patent/AU2021347320A1/en active Pending
- 2021-09-23 JP JP2023518849A patent/JP2023542539A/ja active Pending
- 2021-09-23 CA CA3196823A patent/CA3196823A1/en active Pending
- 2021-09-23 IL IL301634A patent/IL301634A/en unknown
- 2021-09-23 WO PCT/US2021/051734 patent/WO2022066894A1/en not_active Ceased
- 2021-09-23 EP EP21873419.2A patent/EP4216971A4/en active Pending
-
2022
- 2022-03-25 US US17/705,037 patent/US12196744B2/en active Active
-
2024
- 2024-12-06 US US18/972,072 patent/US20250164467A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhong et al. | Cytokines and chemokines in HBV infection | |
| JP2023542539A5 (https=) | ||
| Dorner et al. | Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection | |
| Liew et al. | Role of interleukin 15 and interleukin 18 in inflammatory response | |
| Barnes et al. | Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. | |
| Skinnider et al. | The role of interleukin 13 in classical Hodgkin lymphoma | |
| Smith et al. | Production of interleukin-10 by human bronchogenic carcinoma | |
| Yoo et al. | IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways | |
| Ebrahimi et al. | Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis | |
| Oh et al. | Cytokine regulation of CC and CXC chemokine expression by human astrocytes | |
| Kitaya et al. | Spatial and temporal expression of ligands for CXCR3 and CXCR4 in human endometrium | |
| Sharma et al. | Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma | |
| Fisman et al. | Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof | |
| Lingnau et al. | IL-4 in combination with TGF-β favors an alternative pathway of Th1 development independent of IL-12 | |
| Punnonen et al. | Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors | |
| Wang et al. | Cytokines frequently implicated in myeloproliferative neoplasms | |
| Sotnikova et al. | Cytokine network of eutopic and ectopic endometrium in women with adenomyosis | |
| JP2019536457A5 (https=) | ||
| Schmidt et al. | IL-17 receptor C signaling controls CD4+ TH17 immune responses and tissue injury in immune-mediated kidney diseases | |
| Nath et al. | Macrophage inflammatory protein (MIP) 1 α and MIP1 β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy | |
| Mikita et al. | Recent advances in cytokines in cutaneous and systemic lupus erythematosus | |
| Hou et al. | Rapid downregulation of programmed death‐1 and interferon‐γ‐inducible protein‐10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B | |
| Rosati et al. | Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations | |
| Kennedy et al. | Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis | |
| Wu et al. | The ratio of IP10 to IL-8 in plasma reflects and predicts the response of patients with lung cancer to anti-PD-1 immunotherapy combined with chemotherapy |